Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jun 7:3:286.
doi: 10.1186/2193-1801-3-286. eCollection 2014.

Methylphenidate off-label use and safety

Thierry Trenque  1 , Emmanuelle Herlem  2 , Malak Abou Taam  2 , Moustapha Drame  3
Affiliations

Methylphenidate off-label use and safety

Thierry Trenque et al. Springerplus. .

Abstract

Introduction: Methylphenidate is a piperidine derivative structurally and pharmacologically similar to amphetamine. Methylphenidate is indicated for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 years of age and over when remedial measures alone prove insufficient. In adults, its indication, except in narcolepsy, is not defined. Methylphenidate received regulatory approval almost sixty years ago with a first registration in Switzerland in October 1954.

Objective: To evaluate the off-label use of methylphenidate and its characteristics from a database of spontaneous reports.

Methods: This study analysed data from the French Pharmacovigilance Database of adverse drug reactions spontaneously reported by health professionals from 1985 to December 2011. Off-label use was evaluated according to age.

Results: In the French Pharmacovigilance database, 181 cases of adverse drug reactions were reported with methylphenidate. Neuropsychiatric effects were the most frequent adverse event reported (41%) followed by cardiovascular and cutaneous side effects (14%). 143 reports concerned children (113 boys, 30 girls, mean age 10.6 ± 3.3 years) of which 46 (30%) were off-label uses. There were 38 adults (20 men, 18 women), of which 32 (88%) off-label use. In adults, methylphenidate was prescribed for depression, and this practice was associated with serious adverse events of drug dependence, overdose and suicide attempt. Overall, off-label use was detected in 43% (78/181) of all cases reported.

Conclusion: More than 40% of the patients with drug reactions received methylphenidate for off-label indications. Additional long-term exposures and independent clinical studies are necessary to establish the long-term profile safety of methylphenidate.

Keywords: Methylphenidate; Off-label use.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Profile of the number of spontaneous reports of adverse effects occurring during off-label use of methylphenidate in the French National Pharmacovigilance Database from 1991 to 2011.
See this image and copyright information in PMC

References

    1. Diagnostic and statistical manual of mental disorders, 4th edition, text revision: DSM-IV-TR. Washington, DC: American Psychiatric Association; 2000.
    1. Diagnostic and statistical manual of mental disorders DSM-V. 5. Washington: American Psychiatric Association; 2013.
    1. Andrejak M, Tribouilloy C. Drug-induced valvular heart disease: an update. Arch Cardiovasc Dis. 2013;106:333–339. doi: 10.1016/j.acvd.2013.02.003. - DOI - PubMed
    1. Andrews G, Slade T, Peters L. Classification in psychiatry: ICD-10 versus DSM-IV. Br J Psychiatry. 1999;174:3–5. doi: 10.1192/bjp.174.1.3. - DOI - PubMed
    1. Barkley RA, Fischer M, Smallish L, Fletcher K. The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J Abnorm Psychol. 2002;111:279–289. doi: 10.1037/0021-843X.111.2.279. - DOI - PubMed

LinkOut - more resources